Aqueou hunt device compared with trabeculectomy with Mitomycin-C for children in the firt two year of life

Purpoe To compare the outcome of children 24 month of age or younger treated with aqueou hunt device or with mitomycin-C (MMC) trabeculectomy. Deign Retropective, age-matched, comparative cae erie. Method Forty-ix eye of 32 patient with mean age of 7.0 ± 5.1 month (range, 1 to 22 month) and uncontrolled glaucoma, which received an aqueou hunt device (Ahmed glaucoma valve or Baerveldt implant), compared with 24 eye of 19 patient with mean age of 5.3 ± 4.8 month (range, 0.5 to 24 month), which received an MMC trabeculectomy. urgical ucce wa defined a intraocular preure < 23 mm Hg on maximal glaucoma medication, no further glaucoma urgery performed or recommended, no devatating complication, and table ocular dimenion (axial length and corneal diameter). Reult Cumulative probabilitie of ucce were 87% ± 5.0% for the aqueou hunt group compared with 36% ± 8.0% ucce in the trabeculectomy group at 12 month and 53% ± 12% in the aqueou hunt group compared with 19% ± 7% in the trabeculectomy group at 72 month (χ2 of 23.5, P < .0001). Aqueou hunt implantation wa aociated with ignificantly more potoperative complication requiring a return to the operating room (21 of 46 eye, 45.7%) compared with trabeculectomy with MMC (3 of 24 eye, 12.5%, P = .0074). The mot common potoperative procedure in the aqueou hunt group wa tube repoitioning, performed in 16 of 46 eye (34.8%). Concluion Aqueou hunt implantation offer a ignificantly greater chance of ucceful glaucoma control in the firt 2 year of life, compared with trabeculectomy with MMC. However, the enhanced ucce with aqueou hunt device i aociated with a higher likelihood of potoperative complication requiring urgical reviion, mot commonly tube repoitioning